Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
Target Indication
Acute Pain
Mechanism of Action
NaV1.8 Inhibitor
Clinical Trial
NCT05660538Last updated: 12/3/2025
VRTX
Vertex Pharmaceuticals Incorporated
